The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting

• Verfasst von: Dranitsaris, George [VerfasserIn]
• Verfasst von: Jordan, Karin [VerfasserIn]
• Titel: The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting
• Verf.angabe: G. Dranitsaris, A. Molassiotis, M. Clemons, E. Roeland, L. Schwartzberg, P. Dielenseger, K. Jordan, A. Young & M. Aapro
• E-Jahr: 2017
• Jahr: 07 April 2017
• Umfang: 8 S.
• Fussnoten: Gesehen am 05.09.2018
• Titel Quelle: Enthalten in: Annals of oncology
• Ort Quelle: Amsterdam [u.a. : Elsevier, 1990
• Jahr Quelle: 2017
• Band/Heft Quelle: 28(2017), 6, Seite 1260-1267
• ISSN Quelle: 1569-8041
• DOI: doi:10.1093/annonc/mdx100
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1580706886

Abstract

Background. Despite the availability of effective antiemetics and evidence-based guidelines, up to 40% of cancer patients receiving chemotherapy fail to achiev complete nausea and vomiting control. In addition to type of chemotherapy, several patient-related risk factors for chemotherapy-induced nausea and vomiting (CINV) have been identified. To incorporate these factors into the optimal selection of prophylactic antiemetics, a repeated measures cycle-based model to predict the risk of ≥ grade 2 CINV (≥2 vomiting episodes or a decrease in oral intake due to nausea) from days 0 to 5 post-chemotherapy was developed